Two Healthcare Stocks Are Advancing but See Which One Hedge Funds Sentiment Suggest is Better

Another company, whose stock appreciated today, is Uniqure NV (NASDAQ:QURE). The stock has advanced by over 6% so far today on a volume roughly three times above average. There are no particular moves behind the gains, as the stock of the company that operates in the gene therapy field surged by over 126% since the beginning of the year. A couple of days ago, Chardan Capital reiterated its ‘Buy’ rating on the stock and the overall analyst outlook is bullish with a mean price target of around $40 per share. Among the investors from our database, Uniqure NV (NASDAQ:QURE) is also more popular than TRACON Pharmaceuticals. At the end of June, 17 funds reported holding $87.31 million worth of stock, up from 13 investors holding stakes valued at $49.97 million in aggregate. Moreover, the funds from our database amassed over 15% of the company at the end of June. The second-largest shareholder of Uniqure NV (NASDAQ:QURE) among institutional investors is Joseph Edelman’s Perceptive Advisors, which unloaded around 389,100 shares during the second quarter and reported 650,300 shares in its latest 13F filing. On the other hand, Steve Cohen’s Point72 Asset Management added the company to its equity portfolio and disclosed holding 546,300 shares as of the end of June.

Disclosure: none